Lenalidomide, Pomalidomide and CC-220 Resistant Multiple Myeloma: Confirmation of Role of CRBN/IRF4 Axis and Identification of Multiple Disruption Mechanisms

被引：0
|
作者：
Zhu, Yuan Xiao
Shi, Chang-Xin
Bruins, Laura Ann
Wang, Xuewei
Riggs, Daniel
Porter, Brooke
Ahmann, Jonathan
Braggio, Esteban
Bergsagel, P. Leif
Stewart, A. Keith
机构：
来源：
BLOOD | 2017年 / 130卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
4369
引用
收藏
页数：2
相关论文
共 13 条
  • [1] Iberdomide (CC-220) is a potent cereblon E3 ligase modulator with antitumor and immunostimulatory activities in lenalidomide- and pomalidomide-resistant multiple myeloma cells with dysregulated CRBN
    Bjorklund, Chad C.
    Kang, Jian
    Amatangelo, Michael
    Polonskaia, Ann
    Katz, Mark
    Chiu, Hsiling
    Couto, Suzana
    Wang, Maria
    Ren, Yan
    Ortiz, Maria
    Towfic, Fadi
    Flynt, J. Erin
    Pierceall, William
    Thakurta, Anjan
    LEUKEMIA, 2020, 34 (04) : 1197 - 1201
  • [2] Iberdomide (CC-220) is a potent cereblon E3 ligase modulator with antitumor and immunostimulatory activities in lenalidomide- and pomalidomide-resistant multiple myeloma cells with dysregulated CRBN
    Chad C. Bjorklund
    Jian Kang
    Michael Amatangelo
    Ann Polonskaia
    Mark Katz
    Hsiling Chiu
    Suzana Couto
    Maria Wang
    Yan Ren
    Maria Ortiz
    Fadi Towfic
    J. Erin Flynt
    William Pierceall
    Anjan Thakurta
    Leukemia, 2020, 34 : 1197 - 1201
  • [3] Rate of CRL4CRBN substrate Ikaros and Aiolos degradation underlies differential activity of lenalidomide and pomalidomide in multiple myeloma cells by regulation of c-Myc and IRF4
    Bjorklund, C. C.
    Lu, L.
    Kang, J.
    Hagner, P. R.
    Havens, C. G.
    Amatangelo, M.
    Wang, M.
    Ren, Y.
    Couto, S.
    Breider, M.
    Ning, Y.
    Gandhi, A. K.
    Daniel, T. O.
    Chopra, R.
    Klippel, A.
    Thakurta, A. G.
    BLOOD CANCER JOURNAL, 2015, 5 : e354 - e354
  • [4] Rate of CRL4CRBN substrate Ikaros and Aiolos degradation underlies differential activity of lenalidomide and pomalidomide in multiple myeloma cells by regulation of c-Myc and IRF4
    C C Bjorklund
    L Lu
    J Kang
    P R Hagner
    C G Havens
    M Amatangelo
    M Wang
    Y Ren
    S Couto
    M Breider
    Y Ning
    A K Gandhi
    T O Daniel
    R Chopra
    A Klippel
    A G Thakurta
    Blood Cancer Journal, 2015, 5 : e354 - e354
  • [5] TREATMENT WITH LENALIDOMIDE OVERCOMES THE POOR PREDICTIVE INFLUENCE OF HIGH IRF4 IN PATIENTS WITH MULTIPLE MYELOMA
    Heintel, D.
    Schreder, M.
    Bolomsky, A.
    Hilgarth, B.
    Zojer, N.
    Gisslinger, H.
    Ludwig, H.
    Jaeger, U.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 144 - 145
  • [6] Lenalidomide Inhibits the Multiple Myeloma Cell Survival Factor IRF4/MUM1
    Lopez-Girona, A.
    Mendy, D.
    Gaidarova, S.
    Brady, H.
    CLINICAL LYMPHOMA & MYELOMA, 2009, 9 : S122 - S122
  • [7] Lenalidomide inhibits the multiple myeloma cell-survival factor IRF4/MUM1
    Lopez-Girona, Antonia
    Mendy, Derek
    Brady, Helen
    Gaidarova, Svetlana
    CANCER RESEARCH, 2009, 69
  • [8] IMiDs Synergize with EP300 Inhibition to Disrupt the Ikzf/MYC/IRF4 Axis in Multiple Myeloma
    Welsh, Seth J.
    Barwick, Benjamin G.
    Meermeier, Erin
    Riggs, Daniel
    Shi, Chang-Xin
    Zhu, Yuan Xiao
    Sharik, Meaghen E.
    Du, Megan T.
    Garbitt, Victoria Marie
    Stein, Caleb K.
    Petit, Joachim L.
    Meurice, Nathalie
    Fonseca, Rodrigo
    Todd, Kennedi
    Brown, Sochilt
    Alvarado, Yuliza Tafoya
    Hammond, Zachary
    Cuc, Nicklus
    Wittenberg, Courtney
    Herzog, Camille
    Boise, Lawrence H.
    Bahlis, Nizar J.
    Neri, Paola
    Kuehl, W. Michael
    Chesi, Marta
    Bergsagel, P. Leif
    BLOOD, 2022, 140 : 12997 - 12997
  • [9] Crucial role of HO-1/IRF4-dependent apoptosis induced by panobinostat and lenalidomide in multiple myeloma
    Tang, Sishi
    Ma, Dan
    Cheng, Bingqing
    Fang, Qing
    Kuang, Xingyi
    Yu, Kunling
    Wang, Weili
    Hu, Bo
    Wang, Jishi
    EXPERIMENTAL CELL RESEARCH, 2018, 363 (02) : 196 - 207
  • [10] CC-220 Is a Potent Cereblon Modulating Agent That Displays Anti-Proliferative, Pro-Apoptotic and Immunomodulatory Activity on Sensitive and Resistant Multiple Myeloma Cell Lines
    Bjorklund, Chad C.
    Kang, Jian
    Lu, Ling
    Amatangelo, Michael
    Chiu, Hsiling
    Gandhi, Anita K.
    Pourdehnad, Michael
    Klippel, Anke
    Thakurta, Anjan
    BLOOD, 2016, 128 (22)
12